Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Forvis Mazars Wealth Advisors LLC

Forvis Mazars Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,255 shares of the biopharmaceutical company’s stock after purchasing an additional 41 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,319,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of REGN. State Street Corp increased its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after acquiring an additional 11,499 shares in the last quarter. Swiss National Bank increased its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares in the last quarter. Finally, National Pension Service lifted its stake in Regeneron Pharmaceuticals by 17.0% during the third quarter. National Pension Service now owns 223,617 shares of the biopharmaceutical company’s stock worth $235,075,000 after purchasing an additional 32,457 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $700.33 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $76.56 billion, a PE ratio of 18.29, a P/E/G ratio of 2.34 and a beta of 0.08. The company’s 50 day simple moving average is $699.40 and its 200 day simple moving average is $881.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm earned $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on REGN shares. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.